written on 08.05.2014

Lundbeck makes $658M bid for Chelsea, gaining once-rejected dizziness drug Northera


One day after announcing a drop in quarterly sales and profits, Danish drugmaker Lundbeck said it will pick up Chelsea Therapeutics for cash and contingent value rights in a deal worth up to $658 million.

Latest Reports